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Abstract
Purpose of Review Classification and nomenclature of neuroendocrine neoplasms (NEN) have frequently changed over the last
years. These changes reflect both increasing knowledge and international standardisation.
Recent Findings The most recent changes in the Gastro-Entero-Pancreatic system induced the concept of well-differentiated
NET with high proliferation rate (NET G3), explaining partially the heterogeneity of G3 NEN. Even if the nomenclature in
pulmonary NEN is still different, the terms ‘carcinoid’ and ‘atypical carcinoid’ are widely overlapping with NET G1 and NET
G2. Molecular data shows an additional heterogeneity both in well-differentiated NET and poorly differentiated NEC. However,
no studies are available demonstrating clinical usefulness yet.
Summary The heterogeneity of NEN regarding the organ of origin, differentiation and molecular subtypes make development of
personalised therapy a challenge needing more international and interdisciplinary collaborations and clinical trials allowing
stratification according to biological subgroups.
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Introduction
Historical Aspects
Neuroendocrine neoplasms (NENs) with an incidence of
7/100,000 per year [1] are rare and account for 3% of all
cancers [2]. These 3% of cancers are furthermore distributed
across the entire body, come in ‘low-grade’ and ‘high-grade’
flavours and therefore include a plethora of diagnoses. The
incidence of NEN is highest in the lung and gastroenteropan-
creatic (GEP) system; therefore, nomenclature of these sys-
tems is often used in the rest of the body in analogy. From the
description of the carcinoid tumour (of the ileum) by
Oberndorfer in 1907 [3], the nomenclature has been devel-
oped by pathologists, specialised in specific organs and locat-
ed in different countries, leading to a wide range of different
names for similar tumours. These differences made compari-
son of studies and clinical trials very difficult. The concept to
discriminate benign NEN from borderline and malignant
NEN has additionally led to an uncertainty of what to register
in individual cancer registries and if yes, how to register, lead-
ing to incomplete population based data. Over the last years,
major efforts have led to a standardisation of nomenclature
worldwide including the acceptance of the term neuroendo-
crine neoplasms (NENs), but there are still two mainstays of
nomenclatures used across organs, the ‘GEP-NEN’ and the
‘lung carcinoid’ system. A convergence of these two systems
is a strategic aim of future World Health Organisation (WHO)
classifications [4••]. The following sections will focus on ma-
jor classification changes of these neoplasms, underlining the
progress of understanding them. During the same time, the




1 Institute of Pathology, University of Bern, Murtenstrasse 31,
3008 Bern, Switzerland
2 Department of Visceral Surgery and Medicine, Inselspital Bern
University Hospital, University of Bern, Bern, Switzerland
3 Department of Medical Oncology, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
4 Department of Diabetes, Endocrinology, Nutritional Medicine and
Metabolism, Inselspital, Bern University Hospital and University of
Bern, Bern, Switzerland
https://doi.org/10.1007/s11912-021-01062-6
/ Published online: 14 April 2021
Current Oncology Reports (2021) 23: 65
level of details of pathological reports has dramatically in-
creased as in other tumour entities, and synoptic reports are
becoming more important tools to support pathologists, but
also to allow a further use of the report data for clinical judge-
ment, scientific projects and cancer reporting/registers [5, 6].
NEN Classification Changes
There were not many changes of nomenclature before
2000: The WHO classification of 1980 used the terms islet
cell adenoma/carcinoma, carcinoid and tumours of the dif-
fuse endocrine system for pancreatic neuroendocrine tu-
mours, depending on the cell of origin. The difference be-
tween ‘adenoma’ and ‘carcinoma’ was based on absence or
presence of metastases. The first reports of risk assessment
in NET by measuring proliferation using the cell cycle
marker Ki-67 were published for Lung NET by Costes
et al [7], followed by Pelosi et al. in pancreatic NET in
1996 [8]. In the WHO 2000 classification, the term well-
differentiated endocrine tumour (ET) was introduced to
replace the many different names based on putative cells
of origin. The WHO 2004 classification did take account
for different risks of progression; therefore, ETs were
subdivided into ET of benign behaviour, ET of uncertain
behaviour (increased Ki-67 and/or size and/or invasion)
and well-differentiated endocrine carcinomas (presence of
metastases). This concept of ‘uncertain behaviour’ did nev-
er find acceptance in the USA where this nomenclature
change was not accepted, and still, many other terms were
used. The European Neuroendocrine Tumor Society
(ENETS) allowed in interdisciplinary consensus meetings
in Frascati, Italy, to propose a system of grading based on
proliferation (both mitotic index and Ki-67 index) as well
as a TNM staging system. This proposition implied that all
NETs bear some risk of metastases, however with impor-
tant risk groups. Finally, the black-and-white separation
between benign and malignant was gone, without needing
to state it explicitly. A further relevant step of international
standardisation in the GEP-NEN system was achieved with
the WHO 2010 classification. On both sides of the
Atlantic, the terms well-differentiated neuroendocrine tu-
mour (NET) and poorly differentiated neuroendocrine car-
cinoma (NEC) were introduced, as was the overarching
concept of neuroendocrine neoplasia (NEN) for the sum
of the two biologically/genetically non-related entities.
From this point of time onwards, diagnosis of the tumour
entity (NET vs. NEC) was finally separated from grading
and staging, as for other carcinomas. The Union
Internationale Contre le cancer (UICC) and the American
Joint Committee on Cancer (AJCC) largely followed the
ENETS proposal and introduced a staging system for NET
in the 7th edition [9]. Based on the different biology, for
NEC, the staging of adenocarcinomas was and still is to be
applied. Only after this separation it became increasingly
apparent clinically, that not all NEN G3 are the same. A
subgroup o f panc rea t i c NEN (PanNEN) G3 i s
characterised by similar driver mutations as NET, and
these seem to respond less to platinum-based therapy,
and median survival is longer [10]. The separation of
NET G3 from NEC G3 was defined in the pancreas first
in the WHO 2017 classification and adapted to the entire
GEP-system in the most recent WHO 2019 classification
[10] (Fig. 1). This process of classification development
was frequently driven by the pancreas, as most of the trans-
lational research activities focus on this site.
In contrast to all these changes in the GEP system, the
classification of NEN of bronchopulmonary origin remained
unchanged. The separation between typical carcinoid, atypical
carcinoid and small cell/large cell neuroendocrine carcinoma
is still used, still based on mitotic count and necrosis, and a
clinically useful staging system for carcinoids and atypical
carcinoids is still to be defined. The actual classifications of
GEP-NEN and pulmonary NEN are summarised in Table 1.
Evolution of Reporting Standards
While a decade ago tumour entity and distance to resection
margins represented the main content of pathology reports,
nowadays, increasing histopathological details are needed
for optimal clinical treatment. Minimum diagnostic require-
ments defined by the ENETS-standard of care guidelines
comprise definition and immunohistochemical confirmation
of neuroendocrine phenotype, differentiation, grading and
staging of the neoplasm [13]. As most of the translational
research is performed in PanNEN, a focus on this entity is
given in the following sections.
Biomarkers
Diagnostic
In order to better differentiate and stratify NEN, several bio-
markers have gained clinical relevance in the field of NEN
over the last years (Table 2). First of all, neuroendocrine
markers including Synaptophysin and Chromogranin A de-
fine the neuroendocrine phenotype [19]. CD56 is of minor
relevance due to a lack of specificity. In order to estimate
biological aggression, the mitotic count (per mm2) and the
proliferation index Ki67 are important markers [20, 21].
Ki67 should be assessed in hotspots [4••] and preferably in
manual or automatic counting as ‘eyeballing’ is not reliable
[22, 23].
In the setting of functional NEN, detection of hormones
may be of importance [24, 25]. Especially in the setting of
multiple neuroendocrine tumours, such as in the Multiple
Endocrine Neoplasia Type 1 (MEN1) syndrome, expression
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analysis of glucagon, insulin, gastrin and pancreatic polypep-
tide allows identification of which one is the tumour respon-
sible for a hormonal syndrome.
In the context of metastatic NET of unknown primary,
the set of transcription factors Islet-1, CDX2 and Thyroid
transcription factor-1 may point towards a primary in the
pancreas, small intestine or lung/thyroid respectively [15,
26].
Also, Somatostatin receptor 2A (SSTR2A) is a useful
marker in NEN. SSTR2A is usually expressed in well-
differentiated NEN and seems to be of prognostic value
[27–29]. Furthermore, its expression has direct clinical impact
as it might guide to peptide receptor radionuclide therapy
(PRRT), mostly in metastatic or locally advanced,
unresectable NEN [30]. Most of the approved high-energy
radiopharmaceuticals have good receptor affinity for the
SSTR2 receptor [31].
Mainly for the gastrointestinal tract, the differentiation be-
tween NET and NEC has improved due to new molecular-
genetic insights. In NEC, the most aggressive forms of NEN,
p53 and retinoblastoma protein 1 (RB1) have turned out to be
important biomarkers. Aberrant p53 expression (TP53 inacti-
vation) and the loss of RB are designated as features of pan-
creatic and gastrointestinal NEC [32–34]. RB protein and p53
expression can be investigated by immunohistochemistry. In
addition, NECs share mutations (i.e. KRAS; SMAD4 in the
pancreas, BRAF and K-Ras in the colon) with respective
adenocarcinomas.
Table 1 Gastroenteropancreatic Neuroendocrine Neoplasia (GEP-
NEN, WHO 2019) vs. nomenclature of lung NEN (WHO 2015): The
comparison of the two organ systems reveals that definition criteria of
well-differentiated NET G1 and typical carcinoid of the lung as well as
well-differentiated NET G2 and atypical carcinoid are similar but not
identic. Necrosis has no significant relevance in GEP-NEN. More
aggressive tumours, i.e. NEC and SCLC, have a wide mutational
spectrum, with similar mutations in GEP- and lung NEN
GEP-NEN (WHO 2019) [11] Lung NEN
(WHO 2015) [12]
Defining features Defining features

















































Combined carcinoma At least 10% of each
DIPNECH diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, MiNEN mixed neuroendocrine-non-neuroendocrine neoplasm, NEC neuro-
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Prognostic
The most frequently used prognostic biomarker is Ki-67,
which is the basis for grading of NEN. For pancreatic NET,
many other prognostic biomarkers have been described to
characterise more aggressive PanNET correlating to hypoxia
[16], and stemness [17]; however, they have never found their
way to clinical use. In recent years, alternative lengthening of
telomeres (ALT) and loss of DAXX (death-domain associated
protein) or ATRX (α-thalassemia mental retardation syn-
drome X-linked protein) were shown consistently to be asso-
ciated with adverse outcome in resected PanNET [14, 35•,
36]. Loss of expression of either proteins correlates with
higher tumour stage and grade [37].
In PanNET, an association of inflammatory features
with prognosis becomes more evident. In pancreatic
NEN, PD-L1 expression was associated with higher tu-
mour grade [38], and strong expression was seen mostly
in G3 NET. Cai et al. [39] describe the correlation of
tumour-associated macrophages (TAMs) with reduced
disease-free survival.
Several prognostic biomarkers have been described on the
epigenetic level (see “Epigenetics”).
Predictive
While there is a series of approved drugs for treatment of
metastasised NET, there is no predictive marker available.
In particular, for tyrosin kinase receptor and mTOR inhib-
itors, a reliable clinical response prediction is missing. The
expression of somatostatin-receptors, usually measured by
molecular imaging (DOTA-SSA-PET/CT), is both
prognostic and needed for somatostatin-receptor–targeted
therapy. Regarding response prediction, SSTR2 expression
is the best established factor in clinical routine as it might
be indicative for treatment response with somatostatin an-
alogues [40, 41].
Synoptic Reporting
Synoptic reporting is a standardised reporting format ini-
tially as defined by national societies such as by the
College of American Pathologists (CAP) [42] or the
Royal College of Pathologists (RCP) [43]. Synoptic re-
ports consist of essential reporting elements as defined
by national or international expert panels, which are to
be reported in a reproducible value-like format. The
International Collaboration on Cancer Reporting (ICCR)
was founded by major pathology organisations from
around the world for international standardisation.
Regular updates are planned in a well-defined framework
and aligned with WHO classification updates of tumours.
While ICCR is still focusing on the most frequent cancer
types, synoptic reports for NEN are available and regu-
larly updated by CAP and RCP. In a structured way,
synoptic reports for NEN begin with the TNM classifi-
cation and grading. Tumour grading is further explained
in a separate paragraph subdivided into Ki67 labelling
index and mitotic count according to WHO guidelines.
Later tumour invasion and resection margins are
specified.
Synoptic reports do not exclude to report data points in
addition to required data elements; therefore, in-house ad-
aptations are feasible. It has been shown repeatedly that
Table 2 Diagnostic, prognostic and predictive biomarkers













CA9, microvessel density [16],
DAXX/ATRX loss, CK19/c-Kit
[17],
epigenetic groups, cell of origin
[18]




CA9 carboanhydrase 9, Chr. chromosome, CK19 Cytokeratin 19, c-KIT tyrosine-protein kinase kit, DAXX/ATRX α-thalassemia mental retardation
syndrome X-linked protein/ death-domain–associated protein, MEN1 multiple endocrine neoplasia type 1, MGMT O6 -methylguanine DNA methyl-
transferase, NEC neuroendocrine carcinoma, NEN neuroendocrine neoplasia, RB1 retinoblastoma protein 1, SSTR Somatostatin receptor(s), TTF-1
thyroid transcription factor-1
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synoptic reports increase the completeness of pathology




Epigenetic changes are DNA modification, which do not af-
fect the DNA sequence. They comprise DNA methylation,
histone modifications or posttranscriptional control by
microRNAs [45, 46]. In the last decade, the influence of epi-
genetic factors has been described in small intestinal NET,
lung NET and PanNET [18, 33]. Notably, the majority of
PanNET present with mutation in MEN1, DAXX and ATRX,
which all encode for proteins involved in epigenetic
regulation.
Epigenetic features, such as histone marks, signatures of
super-enhancers as well as similarities of DNA methyla-
tion patterns to normal α- and β-cells have revealed at
least three groups of PanNET with distinct cell of origin,
clinical features and genetic background. Early-stage tu-
mours, with MEN1 mutation, show a clear α-like epige-
netic features and favourable outcome while benign
insulinoma resemble β-cells. Tumours mutated in DAXX
or ATRX showed an intermediate epigenetic profile but
retaining α-like features. Intermediate ADM tumours have
a poor prognosis [18, 47].
Mutational Profiles
The mutational landscape of PanNET, lung NET and ileal
NET is well established. All well-differentiated NETs show
a very low mutational burden. PanNET shows the highest rate
of detectable driver mutations, mainly belonging to genes in-
volved in DNA damage repair (5%), chromatin modification
(40%), altered telomere length (40%) and mTOR signalling
(15%) [48••]. In contrast, only <10% of ileal NET show re-
curring driver mutations. Besides CKN1B, many ileal NETs
seem to carry private mutations. Lung NETs also have muta-
tions in epigenetic modifiers such as ARID1A and others [49].
Alcala et al. have coined the term ‘supra-carcinoids’ [50•].
Supra-carcinoids seem to be a link between carcinoids and
more aggressive large cell carcinomas, as their histopathology
is similar to carcinoids, but the molecular phenotype the one
of large cell NEC [50•]. Consensus in lung NEN nomencla-
ture has not been reached so far.
The mutational spectrum is different in poorly differentiat-
ed NEC, where frequent mutations of TP53, inactivation of
RB1 and mutations of adenocarcinomas of the respective or-
gan such as K-Ras, BRAF are found [51].
Transcriptomic Subgroups
Transcriptomic studies in mouse and human PanNET could
reveal three subtypes: ‘well-differentiated islet tumours’ or
‘insulinoma-like’ (IT), ‘intermediate’ and ‘metastasis-like pri-
mary’ [52]. The MLP subtype is more aggressive and
characterised by features of hypoxia, stemness and an
immune-related phenotype of viral mimicry [48••, 52–54].
Due to a lack of potential predictive value, none of these
molecular markers have found application into clinical
practice.
Poorly differentiated pulmonary NEC, small cell lung
cancer and large cell neuroendocrine lung cancer show
three subgroups with different transcriptomic profiles of
NOTCH signalling, neuroendocrine profile, metabolism
and cell cycle [55]. On a mutational level, group 1 is
characterised by STK11/KEAP1 mutations, groups 2
(mainly large cell NEC) and 3 (mainly small cell NEC)
are characterised by RB mutation or loss of expression
and P16 (CDKN2A) mutation. There seems to be some
association of absence of RB1 mutation/loss and better
response to chemotherapy including platinum and
gemcitabine or taxanes [56].
Conclusions
The histopathological classification has developed step-
wise to the concepts of NEN of different grades, with dif-
ferent mutational spectra depending on organ site. Rarely,
NEN can also have high proliferation rates and are classi-
fied as NET G3 due to morphological, clinical and genetic
similarities to well-differentiated NET of low proliferative
activity.
Poorly differentiated NECs are separated due to a different
biology, morphology and genetics closer to adenocarcinomas
of the respective organs than to NET.
Molecular data demonstrates that these morphological
groups are still heterogeneous based on mutational, epi-
genetic and transcriptomic (also proteomic and
metabolomic) features. This biological heterogeneity is
not taken into account by actual treatment options, as
many NETs are treated in very similar ways, and NECs
are treated mainly in analogy to data from lung
tumours.
While the morphological classification seems to be at a
state of maturity, further efforts are needed to benefit from
the feasible and established molecular classifications with re-
spect to therapy indication and response. Therefore, it is fore-
seeable that in addition to actual classification, reporting of
biomarkers or molecular subgroups will be of increasing
importance.
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